Wave Life Sciences is trading 5.06% lower at $4.13, and the specific cause of the decline is unclear.
- The company announced initiation of a Phase 2a WVE-007 obesity combination trial with tirzepatide on September 23, 2026; available coverage does not explicitly connect it to the decline.
- Biotech is rising 2.07%, while major indexes are modestly lower.